Jerome Powell doubles down on a word that has haunted him, saying pain from tariffs would be ‘transitory’
The Fed’s slowness to catch the inflation surge that began during the pandemic has earned it scads of criticism. Is this time different?
Global markets are rallying on Wall Street's pain — but others are deep in the red
US President Donald Trump's trade war is already causing market jitters, particularly in export-focused Asia.
Biotech's Atai Life Sciences Joins Roster of Firms With Bitcoin Treasury Strategies
Christian Angermayer, the firm’s chairman, stated that it will acquire $5 million in BTC.
Biotech's ATAI Life Sciences Joins Roster of Firms With Bitcoin Treasury Strategies
Christian Angermayer, the firm’s chairman, stated that it will acquire $5 million in BTC.
Wall Street Uncertain Over When Fed's Balance-Sheet Unwind Will End
(Bloomberg) -- The Federal Reserve’s decision to cut the pace of its balance-sheet unwind is leading some Wall Street strategists — including those at Barclays and Bank of America — to push out their expectations for how long the central bank’s runoff will go on. Most Read from BloombergNew York Subway Ditches MetroCard After 32 Years for Tap-And-GoAmtrak CEO Departs Amid Threats of a Transit Funding PullbackDespite Cost-Cutting Moves, Trump Plans to Remake DC in His StyleLA Faces $1 Billion Bud
BusinessEurope: Why Europe’s economy is on a make-or-break knife-edge
Boosting competitiveness in the face of weak growth and tariff threats is now a matter of urgency, says business chief.View on euronews
Inside Pump.fun's Plan to Dominate Solana DeFi Trading
Solana's most profitable protocol Pump.fun is gunning for an even greater share of the chain's DeFi economy.
Telegram-based blockchain TON raises $400 million from prominent crypto VCs
The investors will receive “token-based investments” in lieu of equity.
Factbox-Lilly's weight-loss drug launch in India to energize rivals eyeing mega market
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug: NOVO NORDISK The Danish drugmaker had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026. The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India. Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply.
Tesla is struggling. One Wall Street analyst sees red-state EV buyers coming to the rescue.
"Tesla could actually net meaningful sales gains over time," TD Cowen analysts wrote this week. Sales could ultimately grow in markets with lower EV adoption.
Popular Post
- Tokenized Treasury Funds Pass $2B Market Cap Amid BlackRock’s Explosive Growth Aug 26, 2024
- 3 Dawdling Stocks Walking a Fine Line Apr 28, 2025
- 3 Reasons to Avoid PEP and 1 Stock to Buy Instead Apr 10, 2025